Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION CMC change-control owner is responsible for to drop a secondary in a mid-size sponsor after a complete response letter, using complete-response-letter deficiency list as the only working extract. A competitor label that just got a narrower indication is what reset the timeline for this Pharma & Life Sciences Pharmacovigilance file.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. CMC change-control owner can defend Proceed under protocol from complete-response-letter deficiency list after a competitor label that just got a narrower indication in a Pharma & Life Sciences challenge. 2. CMC change-control owner cannot defend Proceed under protocol from complete-response-letter deficiency list; Pause the pathway is what the extract actually supports after a competitor label that just got a narrower indication. 3. A competitor label that just got a narrower indication never reached the population in complete-response-letter deficiency list — reopen intake, do not close to drop a secondary. 4. Two facts in complete-response-letter deficiency list after a competitor label that just got a narrower indication conflict for CMC change-control owner; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Check whether complete-response-letter deficiency list supports the labeled claim CMC change-control owner would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a competitor label that just got a narrower indication. 4. For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a competitor label that just got a narrower indication). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for CMC change-control owner - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for CMC change-control owner in a mid-size sponsor after a complete response letter